Nadine C. Salisch

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Journal: Vaccines

Published: July 02, 2026

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines.

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines.

Journal: NPJ vaccines

Published: December 05, 2025

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.

Journal: Open forum infectious diseases

Published: June 20, 2024

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.

Journal: Vaccine

Published: April 23, 2024

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1.

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1.

Journal: Cell reports

Published: February 23, 2024

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses.

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses.

Journal: PloS one

Published: September 18, 2023

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets.

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets.

Journal: NPJ vaccines

Published: June 09, 2022

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes.

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes.

Journal: Science immunology

Published: June 02, 2022

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

Journal: The Journal of infectious diseases

Published: April 20, 2022

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.

Journal: Annals of internal medicine

Published: February 15, 2021

Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.

Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.

Journal: Vaccines

Published: October 06, 2020

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations.

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations.

Journal: NPJ vaccines

Published: April 18, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026